Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117177 | 0.83 | GAA (0.63) | GAAKDM4EPOLBRAB9ANPC1 | |
| SCHEMBL21356112 | 0.83 | GAA (0.63) | GAAKDM4EPOLBRAB9ANPC1 | |
| SCHEMBL3542064 | 0.81 | GAA (0.60) | GAAKDM4EPOLBRAB9ANPC1 | |
| SCHEMBL3369735 | 0.81 | PTGS1 (0.41) | GAAKDM4EPOLBRAB9ANPC1 | |
| SCHEMBL3033258 | 0.81 | GAA (0.75) | GAAKDM4EPOLBRAB9ANPC1 | |
| SCHEMBL21354875 | 0.79 | GAA (0.61) | GAAKDM4EPOLBRAB9ANPC1 | |
| SCHEMBL118187 | 0.78 | GAA (0.75) | GAAKDM4EPOLBRAB9ANPC1 | |
| SCHEMBL3545619 | 0.77 | KDM4E (0.64) | GAAKDM4EPOLBRAB9ANPC1 | |
| SCHEMBL101291 | 0.77 | GAA (1.00) | GAAKDM4EPOLBRAB9ANPC1 | |
| SCHEMBL3499867 | 0.77 | GABRA2 (0.57) | GAAKDM4EPOLBRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404848-B2 | Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics | SANOFI (FR) | 2013-03-26 | — | — | US | disclosed |
| US-7704989-B2 | Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-04-27 | — | — | US | disclosed |
| US-20090149441-A1 | DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149441-A1 | DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | NR4A2, NR4A3, NCOR1 | GAA 4805/4885KDM4E 2303/4885POLB 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.